Edition:
United States

Chiome Bioscience Inc (4583.T)

4583.T on Tokyo Stock Exchange

365JPY
15 Dec 2017
Change (% chg)

¥1 (+0.27%)
Prev Close
¥364
Open
¥368
Day's High
¥372
Day's Low
¥363
Volume
448,300
Avg. Vol
155,063
52-wk High
¥533
52-wk Low
¥358

Chart for

About

Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in three business segments. The Drug Discovery Alliance segment is engaged in the research and development of antibodies which aims at the development of... (more)
No analyst recommendations are available for .

Overall

Beta: 2.62
Market Cap(Mil.): ¥9,775.25
Shares Outstanding(Mil.): 26.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Chiome Bioscience to sign joint research agreement with Trans Chromosomics

* Says it plans to sign 2-year joint research agreement with Trans Chromosomics Inc, for human antibody related product

Dec 14 2017

BRIEF-Chiome Bioscience signs license agreement related to antibody LIV-1205 for cancer treatment

* Says it signed license agreement with ADC Therapeutics SA, regarding development, manufacture and sale of Antibody Drug Conjugate of antibody LIV-1205 for cancer treatment

Sep 27 2017

BRIEF-Chiome Bioscience receives decision to grant TROP-2 antibody related patent in Europe

* Says it received a decision to grant patent for Anti-Human Trop-2 Antibody Having Antitumor Activity in Vivo,(application No. 11783675.9) in Europe, on Sept. 6

Sep 06 2017

BRIEF-Chiome Bioscience receives patent in China regarding DLK-1 antibody

* Says it received a patent (No.201380051895.5) regarding DLK-1 antibody in China

Jul 21 2017

BRIEF- Chiome Bioscience announces exercise of options

* Says 820 units of its 13th series options were exercised to 820,000 shares of its common stock from June 1 to June 27

Jun 27 2017

Earnings vs. Estimates